Lonafarnib is a farnesyltransferase inhibitor classified as an antiproteinopathy agent, primarily utilized to reduce the risk of mortality in patients with Hutchinson-Gilford progeria syndrome and to treat… Read more
Lonafarnib is a farnesyltransferase inhibitor classified as an antiproteinopathy agent, primarily utilized to reduce the risk of mortality in patients with Hutchinson-Gilford progeria syndrome and to treat specific processing-deficient progeroid laminopathies. This category provides essential compounds for researchers and quality control laboratories, including the active pharmaceutical ingredient, related process and degradation impurities like dehydrolonafarnib and Lonafarnib Impurity 1, and stable isotope-labelled standards such as Lonafarnib-d9 and rac-Lonafarnib-d4. These high-purity materials are critical for accurate impurity profiling, method validation, and quantitative analysis within pharmaceutical research. Laboratories rely on these specific reference standards to support rigorous quality control and developmental studies, ensuring consistent performance throughout the lifecycle of the drug substance.